First Tracks Biotherapeutics (TRAX) Stock Forecast & Price Target
Score
First Tracks Biotherapeutics Inc price target
| TRAX | |
|---|---|
| Low | $57.00 |
| Average | $71.33 |
| High | $100.00 |
| Upside vs current price | +51.4% |
The average target of $71.33 is +51.4% versus the current TRAX price of $47.10.
First Tracks Biotherapeutics Inc analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 3 |
| Buy | 9 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
12 analysts cover TRAX.
First Tracks Biotherapeutics Inc EPS and revenue estimates
The estimate table for the First Tracks Biotherapeutics Inc keeps 2026 EPS $-4.12, 2027 EPS $-3.68, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-4.12 | $75.00M |
| 2027 | $-3.68 | — |
Is First Tracks Biotherapeutics Inc a buy or sell?
Of the 12 analysts covering First Tracks Biotherapeutics Inc, 12 rate it a buy (3 strong buy and 9 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The TRAX consensus label is Buy, beside 12 buy-side ratings and 0 sell-side ratings.
The average target of $71.33 implies +51.4% versus the current price of $47.10.
the First Tracks Biotherapeutics Inc closes with 12 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the First Tracks Biotherapeutics Inc forecast
Analysts are far apart on TRAX. The published low is $57.00, the average is $71.33, and the high is $100.00.
From today's $47.10 print, the TRAX average target is +51.4% away.
Most of the TRAX coverage agrees: 12 of 12 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
TRAX targets have eased: $62.40 in the last month against $69.00 over the last quarter.
TRAX coverage is thin at 12 analysts, and one revision moves the average.
First Tracks Biotherapeutics Inc forecast questions
What is the TRAX price target?
The published range for TRAX is $57.00 to $100.00, with an average of $71.33. That average is +51.4% versus the current price of $47.10.
Is First Tracks Biotherapeutics Inc a buy or sell?
Of the 12 analysts covering First Tracks Biotherapeutics Inc, 12 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for TRAX is 12 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for First Tracks Biotherapeutics Inc?
Analyst EPS estimates for First Tracks Biotherapeutics Inc: 2026 $-4.12, 2027 $-3.68.
What is the revenue estimate for First Tracks Biotherapeutics Inc?
Analyst revenue estimates for First Tracks Biotherapeutics Inc: 2026 $75.00M.
How many analysts cover TRAX?
12 analysts cover TRAX. Their consensus on TRAX is Buy, across those 12.